ADMA: Vanguard Amends 13G to Report 0 Shares
ADMA Biologics Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ADMA Biologics Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock. The amendment states that, following an 01/12/2026 internal realignment, certain Vanguard subsidiaries now report holdings separately and The Vanguard Group no longer reports beneficial ownership of those subsidiary holdings.
The filing is an ownership clarification by an institutional investor and does not disclose purchases or sales of ADMA shares in this amendment.
Insights
Amendment reflects reporting reallocation within Vanguard, not a market trade.
The filing documents an internal reorganization at The Vanguard Group that led to disaggregated reporting for subsidiaries; the amendment reports 0 shares beneficially owned by The Vanguard Group as of the amendment.
Cash‑flow treatment and any trades by Vanguard subsidiaries are not disclosed in this excerpt; subsequent filings from those subsidiaries could show holdings or transactions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report for ADMA (ADMA)?
Which date is referenced for Vanguard's realignment in the filing?
Who signed the Schedule 13G/A amendment for Vanguard?
AI-generated analysis. How Rhea-AI works. Not financial advice.